Evaluation of the effectiveness of remdesivir in treating severe COVID-19 using data from the ISARIC WHO Clinical Characterisation Protocol UK: a prospective, national cohort study.
Arch, B. N.; Kovacs, D.; Scott, J. T.; Jones, A. P.; Harrison, E. M.; Rosala-Hallas, A.; Gamble, C. G.; Openshaw, P. J.; Baillie, J. K.; Semple, M. G.
Show abstract
BackgroundRemdesivir has been evaluated in clinical trial populations, but there is a sparsity of evidence evaluating effectiveness in general populations. MethodsAdults eligible to be treated with remdesivir, requiring oxygen but not ventilated, were identified from UK patients hospitalised with COVID-19. Patients treated with remdesivir within 24h of hospitalisation were compared with propensity-score matched controls; estimates of effectiveness were calculated for short-term outcomes (14-day mortality, 28-day mortality, time-to-recovery among others) using multivariable modelling. Results9,278 out of 39,330 patients satisfied eligibility criteria. 1,549 patients were identified as treated and matched with 4,964 controls. Patients were 62% male, mean (SD) age 63.1 (15.6) years, 80% White ethnicity, and symptomatic for a median of 6 days prior to baseline. There was no statistically significant benefit of remdesivir at 14 days in terms of mortality or clinical status; there were signals of effectiveness in time-to-recovery after day 9, and a reduction in 28-day mortality. ConclusionIn a real-world setting, initiation of remdesivir within 24h of hospitalisation in conjunction with standard of care was not associated with a benefit at 14 days but supports clinical trial evidence of a potential reduction in 28-day mortality.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Trends in fluoroquinolone prescribing in UK primary and secondary care between 2019 and 2023 93%
- Optimal dose and safety of molnupiravir in patients with early SARS-CoV-2: a phase 1, dose-escalating, randomised controlled study 92%
- General practice antibiotic prescriptions attributable to Respiratory Syncytial Virus by age and antibiotic class: An ecological analysis of the English population 92%
Similar papers in this journal
- Real-World Effectiveness Of Nirmatrelvir/Ritonavir On COVID-19-Associated Hospitalization Prevention: A Population-Based Cohort Study In The Province Of Québec, Canada 94%
- Outcomes of COVID-19 related hospitalisation among people with HIV in the ISARIC WHO Clinical Characterisation Protocol UK Protocol: prospective observational study 92%
- Favipiravir for treatment of outpatients with asymptomatic or uncomplicated COVID-19: a double-blind randomized, placebo-controlled, phase 2 trial 92%
Similar papers in this journal
- Adverse effects of remdesivir, hydroxychloroquine, and lopinavir/ritonavir when used for COVID-19: systematic review and meta-analysis of randomized trials 94%
- CATALYST trial protocol: A multicentre, open-label, phase II, multi-arm trial for an early and accelerated evaluation of the potential treatments for COVID-19 in hospitalised adults 93%
- Efficacy of remdesivir versus placebo for the treatment of COVID-19: A protocol for systematic review and meta-analysis of randomized controlled trials 93%
Similar papers in this journal
- Effectiveness of Rosuvastatin plus Colchicine, Emtricitabine/Tenofovir and a combination of them in Hospitalized Patients with SARS Covid-19 96%
- Antiviral efficacy of fluoxetine in early symptomatic COVID-19: an open-label, randomised, controlled, adaptive platform trial (PLATCOV) 94%
- Early treatment with nitazoxanide prevents worsening of mild and moderate COVID-19 and subsequent hospitalization 94%
Similar papers in this journal
- Detailed disease progression of 213 patients hospitalized with Covid-19 in the Czech Republic: An exploratory analysis 95%
- Hydroxychloroquine For The Treatment Of Severe Respiratory Infection By COVID-19: A Randomized Controlled Trial 95%
- Doxycycline for the prevention of progression of COVID-19 to severe disease requiring intensive care unit (ICU) admission: a randomized, controlled, open-label, parallel group trial (DOXPREVENT.ICU) 95%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.